Advancing pipeline of inhaled treprostinil products in clinical studies Strengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare Royalty ...

Theravance Biopharma continued to make progress with the open-label enrollment of its ampreloxetine Phase 3 clinical study for the treatment of symptomatic nOH in patients with Multiple System Atrophy ...

A heavily contaminated cooling tower at a plant in the Lower Rhine Valley was shut down 14 days ago and there have been no ...

After being exposed to toxins from the LA fires, some firefighters are turning to a compounded breathing drug, but it's hard ...

When patients cannot adhere to inhaler instructions — whether because of cognitive or physical limitations — a nebulized LAMA might offer another method to safely deliver medication. To that end, GOLD ...

Following the end of the year, we successfully completed our Phase 2 dose-ranging clinical trial with glycopyrrolate ALAMA, to support a fixed-dose combination with nebulized ensifentrine ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales. See the ...

inhalation solution (nebulized Tyvaso) for the treatment of idiopathic pulmonary fibrosis. Top-line data from the same is expected in the first half of 2026. This might have driven the recent ...

A case study by Wu et al. [23] reported lidocaine toxicity in a 48-kg woman with multiple health conditions receiving nebulized lidocaine before bronchoscopy. She received an approximate total ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers ...